3 results
Approved WMOCompleted
To evaluate the long-term safety, tolerability and efficacy of ArikaceTM 590 mg for a maximum 12 cycles administered once daily, where each cycle consists of 28 days on treatment followed by 28 days off treatment.
Approved WMOCompleted
The primary objective of this Registry is:• To assess the durability of sustained virologic response (SVR) following treatment in a Gilead-sponsored hepatitis C study.The secondary objectives of this Registry are:• To determine whether subsequent…
Approved WMORecruiting
To assess to efficacy of locally applied tacrolimus suppositories compared to beclomethason suppositories in patients with recurrent or refactory ulcerative proctitis.